Our Team Of Experts

Anshul Thakral

Former CCO and EVP, PPD
Board Director for Saama, TriNetX

Carlos Paya

Former CEO of Immune Design, previously Elan, Eli Lilly, and Mayo Clinic

Michael Doherty

Former Chief Regulatory Affairs EQRX, previously Foundation Medicine and Roche

Elisha Talley-Roithner

Former SVP of Development Operations, PPD

James Cornwall

Former CBO, Nuvelution, previously Corporate Development at IQVIA

Matthew Cramblett

Former VP of Development Operations, PPD, previously Nucana

Milena Kanova- Petrova

Former SVP Operations and Chief Compliance Officer, Nuvelution, previously IQVIA

Aaron Camp

Former Global Head of Biostatistics ICON, previously PPD

Siva Mullapudi

Former CRO Services Business Unit Lead, ProSciento, previously Covance and PPD

How We Help

Launch Therapeutics offers pharmaceutical and biotech partners a variety of innovative models that provide capital, development expertise, and access to additional resources. These models offer an aligned and efficient approach to help fund and develop late-stage therapies and accelerate the path to regulatory approval. Launch Tx’s team of experts bring an unrivaled combination of immense commitment, decades of experience, and enthusiastic passion to their work.


Bespoke deal structures taking combination of clinical, regulatory, and commercial risks


Team with deep clinical and regulatory expertise with access to an expansive network


Disruptive model accelerating clinical development and regulatory timelines

Demonstrated Trust and Belief

Launch Therapeutics (Launch Tx) is backed by the respected and experienced professionals at Carlyle and Abingworth. Their investments demonstrate the deep trust and belief they have in Launch Tx to disrupt the development paradigm and expedite the pathway for therapies to be approved and into the hands of patients who need them. 

Carlyle & Abingworth along with our CEO , Anshul Thakral, formed Launch Therapeutics in 2022. By combining the global network of Carlyle and Abingworth with the seasoned team of professionals at Launch Tx, both pharmaceutical and biotech companies have an ideal partner to advance their late-stage clinical programs.